653A9358 kl.jpg

Developing endolysins and phages as therapeutics

Our purpose

Millions of patients suffer from chronic bacterial infections - where antibiotics can only suppress the disease but not cure. At PhagoMed we develop a new generation of precision anti-bacterials that eliminate the pathogen while leaving the microbiome intact. Using our synthetic biology platform, we can design targeted interventions as breakthrough therapies for chronic bacterial infections.

Our lead program PM-477:

Bacterial vaginosis (BV)

Recurrent bacterial vaginosis affects 100 million women across the globe. Today’s therapy relies on long-term suppressive antibiotics that fail to provide a cure. Our engineered lysin works where antibiotics fail and is precise, making it a highly innovative solution.

Patient view - BV.png

Are you suffering from BV?

At PhagoMed, we are working to design the best possible therapies for bacterial vaginosis. If you are willing to share your experience with bacterial vaginosis, please click on the link below to complete the survey.

Bildschirmfoto%202020-06-19%20um%2020.44

About lysins and phages

Phages have been around since the earliest days of evolution. Phages are natural viruses that hunt and infect bacteria. They then use lysins to break open the cell wall and kill the bacteria.

PhagoMed is member of

PhagoMed is supported by

Latest News

PhagoMed Biopharma GmbH

Leberstraße 20

1110 Vienna

Austria

contact@phagomed.com

Imprint & Privacy Policy